Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMY-922
- Development stage
- Phase 1
- Lead developer
- Luminary Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
LMY-922 is an allogeneic, non-viral chimeric antigen receptor (CAR)-T cell therapy developed by Luminary Therapeutics. It is designed to target the B-cell activating factor receptor (BAFF-R), as well as BCMA (B-cell maturation antigen) and TACI (Tumor necrosis factor receptor superfamily member 13B), making it a multi-targeted CAR-T therapy. The drug acts through immunologic cytotoxicity and T lymphocyte replacement mechanisms, aiming to treat autoimmune diseases by depleting pathogenic B cells. Its primary development focus has been on autoimmune disorders such as systemic lupus erythematosus and lupus nephritis. The product utilizes a universal CAR-T platform referred to as Gamma 2.0+ CAR T.
- Other names
- LMY 922LMY922LMY-922
02
Targets
TACI (Tumor necrosis factor receptor superfamily member 13B)TNFRSF13C (B-cell Activating Factor Receptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on LMY-922.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMY-922.